PFE Jun 2024 75.000 call
| Previous Close | 1.3000 |
| Open | 1.2000 |
| Bid | 1.1000 |
| Ask | 1.4800 |
| Strike | 75.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 1.1000 - 1.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 49 |
- Motley Fool
2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market
Rewards that the next bull market will bring are being built right now by farsighted investors who can find opportunities among today's discounted stocks. While there's no telling exactly when a bull market will develop, planting the seeds of success by buying some shares of cheap yet high-quality companies out there right now is a good move. With that in mind, here are two businesses you're probably acquainted with that are priced for a no-brainer purchase -- and have a good shot at flourishing in the next bull market and beyond.
- Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
On that note, Pfizer (NYSE: PFE) has a habit of making its investors wealthier via its dividends and share repurchasing activity, and there's no reason to suspect that'll change through at least 2030. If you invested $5,000 in Pfizer a decade ago, right now you'd be happy to see that its total return in that period was around $10,900. In the next 10 years, there's no guarantee that it'll repeat that exact performance, but there are reasons to believe that it'll still be a good stock to own for the purposes of collecting its dividend and perhaps also experiencing share price appreciation over the long run.
- Investing.com
5 big deal reports: UBS offers to snap up Credit Suisse for $1 billion | Pro Recap
UBS (NYSE:UBS) has offered to buy Credit Suisse (NYSE:CS) for up to $1B in an all-share deal, with the Swiss government planning to change laws to bypass a shareholder vote on the deal, according to a Financial Times report today. The proposed deal is set to be signed as soon as Sunday evening at a fraction of Credit Suisse's closing price on Friday. This week alone, Credit Suisse's shares have dropped more than 24% amid a series of scandals that have led to a decline in investor and client confidence, forcing the company to obtain $54B in central bank funding.
